Evidence map›Paper›PMID 39657040›Full record

ReviewMagyar onkologia2024

[Predictive markers in gynaecological, prostate, and breast cancers].

András Rókusz, Zsombor Melegh, Ildikó Vereczkey, Eszter Papp, Lilla Madaras, Erika Tóth

Abstract readReviewEnglish Abstract
PubMed Full text at PMC
In one paragraph

Review in Magyar onkologia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

András RókuszPatológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, Budapest, Hungary. rokusz.andras@semmelweis.hu.
Zsombor MeleghSebészeti és Molekuláris Patológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
Ildikó VereczkeySebészeti és Molekuláris Patológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
Eszter PappSebészeti és Molekuláris Patológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
Lilla MadarasPatológiai, Igazságügyi és Biztosítási Orvostani Intézet, Semmelweis Egyetem, Budapest, Hungary.
Erika TóthSebészeti és Molekuláris Patológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The implementation of targeted therapies in oncology has brought significant improvement in the treatment of many solid tumours. At the same time, pathological and molecular pathological diagnostics became more important. Today, there are hardly any solid tumours that do not require predictive biomarker testing. In recent years, a number of new targeted therapies have emerged for gynaecological tumours, prostate and breast cancer. In this article, we summarise the molecular pathology tests required in these tumours based on current clinical and pathological guidelines.

Indexed as

Biomarkers, TumorBreast NeoplasmsGenital Neoplasms, FemaleProstatic NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansMaleMolecular Targeted TherapyOvarian NeoplasmsPredictive Value of TestsPrognosisBiomarkers, TumorErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID39657040
PMCPMC11841702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.